Detalles de la búsqueda
1.
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells.
Mol Ther
; 27(5): 933-946, 2019 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30879952
2.
CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process.
Cancer Gene Ther
; 30(10): 1355-1368, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37391502
3.
Surface expression of the immunotherapeutic target GD2 in osteosarcoma depends on cell confluency.
Cancer Rep (Hoboken)
; 4(5): e1394, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33811471
4.
HLA-G and HLA-E Immune Checkpoints Are Widely Expressed in Ewing Sarcoma but Have Limited Functional Impact on the Effector Functions of Antigen-Specific CAR T Cells.
Cancers (Basel)
; 13(12)2021 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34201079
5.
T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G.
Oncotarget
; 9(5): 6536-6549, 2018 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29464090
6.
Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.
Oncoimmunology
; 6(1): e1250050, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28197367
7.
Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function.
Oncol Rep
; 32(2): 845-52, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24927333
Resultados
1 -
7
de 7
1
Próxima >
>>